Page last updated: 2024-08-21

pyrazines and Lymphoma, Mantle-Cell

pyrazines has been researched along with Lymphoma, Mantle-Cell in 140 studies

Research

Studies (140)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	46 (32.86)	29.6817
2010's	86 (61.43)	24.3611
2020's	8 (5.71)	2.80

Authors

Authors	Studies
Meiners, S; Meul, T; Schlesser, C; Stathopoulos, G	1
Casasnovas, O; Damaj, G; Davies, A; Doorduijn, JK; Dupuis, J; Długosz-Danecka, M; Eek, R; Frigault, MM; Goy, A; Izumi, R; Jacobsen, E; Jain, P; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Nguyen, D; Oberic, L; Panizo, C; Patel, P; Robak, T; Rule, S; Shah, B; Smith, SD; Wang, M; Yin, M; Zinzani, PL	1
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J	1
Abu-Rayyan, M; Al-Janazreh, H; Atrash, M; Botta, C; Cutrona, G; Galimberti, S; Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Skafi, M; Vigna, E	1
Campbell, M; Hanna, KS; Husak, A; Sturm, S	1
Badillo, M; Chen, W; Guerrero, M; Nava, D; Rosa, M; Wang, M	1
Bond, DA; Maddocks, KJ	1
Danilov, AV; Persky, DO	1
Badillo, M; Flowers, C; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Li, S; Nair, R; Nastoupil, L; Navsaria, L; Ok, CY; Patel, KM; Tang, G; Vega, F; Wang, L; Wang, ML; Yin, CC; Zhang, S	1
Ando, K; Ennishi, D; Hayashi, N; Ichikawa, S; Iizumi, S; Izutsu, K; Kato, K; Kawasumi, H; Kumagai, K; Murayama, K; Nagai, H; Patel, P; Shibayama, H; Suzumiya, J; Yamamoto, K	1
Dhillon, S; Markham, A	1
Ansell, SM; Kapoor, P	1
Casasnovas, O; Covey, T; Damaj, G; Davies, A; Doorduijn, J; Dua, R; Dupuis, J; Eek, R; Goy, A; Hamdy, A; Huang, X; Izumi, R; Jacobsen, E; Jurczak, W; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Oberic, L; Panizo, C; Patel, P; Robak, T; Rothbaum, W; Rule, S; Shah, B; Slatter, JG; Smith, SD; Wang, M; Zinzani, PL	1
Awan, FT; Jurczak, W	1
Andorsky, DJ; Assouline, S; Forero-Torres, A; Jones, V; Klein, LM; Kolibaba, KS; Patel-Donnelly, D; Sharman, JP; Shi, W; Smith, M; Yasenchak, CA; Ye, W	1
da Cunha-Bang, C; Niemann, CU	1
Długosz-Danecka, M; Jurczak, W; Wang, M	1
Inwards, D; Witzig, TE	1
Alinari, L; Bond, DA; Maddocks, K	1
Bernasconi, E; Bertoni, F; Cascione, L; Dirnhofer, S; Gaudio, E; Gerlach, MM; Mascia, M; Priebe, V; Spriano, F; Stathis, A; Tarantelli, C; Targa, A; Zucca, E	1
Hatano, Y; Ikeda, S; Ito, M; Nara, M; Oshima, K; Sawada, K; Seto, M; Tagawa, H; Teshima, K; Watanabe, A	1
Wang, ZQ; Xie, JL; Zhou, XG	1
Chen, Z; Fayad, L; Kwak, L; McCarty, N; McLaughlin, P; Neelapu, SS; Pittman, EF; Romaguera, J; Wang, M	1
Childs, R; Cook, L; Jaffe, ES; Ramos, C; Vo, P	1
Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L	1
Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Johnston, JS; Li, X; Lin, TS; Lustberg, ME; Porcu, P	1
Bernard, M; Bosq, J; Camara-Clayette, V; Fest, T; Koscielny, S; Lamy, T; Lazar, V; Lenoir, G; Ribrag, V; Roux, S	1
Adami, F; Brancalion, A; Cabrelle, A; Cappellesso, R; Colpo, A; Di Maggio, SA; Gurrieri, C; Mandato, E; Manni, S; Marino, F; Piazza, F; Pizzi, M; Semenzato, G; Trentin, L; Tubi, LQ; Zaffino, F; Zambello, R	1
Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM	1
Advani, RH; Chang, JE; Gascoyne, RD; Horning, SJ; Kahl, BS; Li, H; Paietta, EM; Smith, MR; Yang, DT	1
Blum, KA; Maddocks, K	1
Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN	1
Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E	1
Balsas, P; Campo, E; Colomer, D; Martínez, A; Montraveta, A; Moros, A; Normant, E; Pérez-Galán, P; Rodríguez, V; Roué, G; Saborit-Villarroya, I; Sandy, P; Wiestner, A	1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A	1
Furtado, M; Johnson, R; Kruger, A; Rule, S; Turner, D	1
Campo, E; Rule, S	1
Alexeeva, J; Cavalli, F; Drach, J; Hong, X; Huang, H; Jin, J; Liu, T; Mayer, J; Okamoto, R; Osmanov, E; Pei, L; Pereira, J; Pylypenko, H; Robak, T; Rooney, B; Samoilova, O; Siritanaratkul, N; van de Velde, H; Verhoef, G; Zhu, J	1
Tanday, S	1
Bodo, J; Chen-Kiang, S; Di Liberto, M; Durkin, L; Elemento, O; Eng, K; Hsi, ED; Shetty, S; Smith, MR; Zhao, X	1
Cavalli, F	1
Baccarani, M	1
Jain, H; Sengar, M	1
Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H	1
Cowan, AJ; Frayo, SL; Gopal, AK; Green, DJ; Pagel, JM; Palanca-Wessels, MC; Press, OW	1
Guo, S; Li, X; Qu, F; Tian, C; Xia, B; Yu, Y; Zhang, L; Zhang, Y	1
Kolesar, J; Utecht, KN	1
Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L	1
Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Nguyen, M; Pérez-Galán, P; Roué, G; Shore, GC; Villamor, N	1
Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; Nasta, S; O'Connor, OA; Robertson, MJ; Shi, H	1
Davies-Hill, T; Jin, L; Miida, T; Miyake, K; Pittaluga, S; Raffeld, M; Rudelius, M; Sebasigari, D; Tabe, Y	1
Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Gonen, M; Gordon, L; Hamelers, R; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, JJ; Zelenetz, AD	1
Dreyling, M; Hartmann, E; Hiddemann, W; Hutter, G; Pastore, A; Rieken, M; Rosenwald, A; Weinkauf, M; Zimmermann, Y	1
Bentz, M; Dreyling, M; Hiddemann, W; Jentsch-Ullrich, K; Mueck, R; Rohrberg, R; von Schilling, C; Weidmann, E; Weigert, O	1
Billet, A; Chaby, G; Chatelain, D; Christophe, O; Dadban, A; Damaj, G; Lenglet, A; Lok, C; Marolleau, JP; Royer, R; Thuillier, D; Vaida, I; Viseux, V	1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE	1
Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR	1
Dreyling, M; Issels, R; Lorenz, M; Milani, V; Pastore, A; Rieken, M; Weinkauf, M	1
Hamlin, P; MacGregor-Cortelli, B; Moskowitz, CH; Muzzy, J; O'Connor, O; Schenkein, DP; Straus, D; Trehu, E; Wright, J; Zelenetz, AD	1
Conticello, C; Di Raimondo, F	1
Buda, G; Orciuolo, E; Pelosini, M; Petrini, M	1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, J	1
Bauer, F; Dasanu, CA; Reale, MA	1
Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y	1
Chitambar, CR; Purpi, DP	1
Kahl, BS	1
Bolick, SC; Desai, S; Dessureault, S; Maurin, M; Smith, MA; Sotomayor, E; Tao, J; Wright, KL	1
Brennan, SK; Kowalski, J; Matsui, W; Meade, B; Merchant, AA; Wang, Q	1
Bernstein, SH; Boral, AL; Bryant, B; Fisher, RI; Fleming, MD; Goy, A; McDonald, A; Mulligan, G; Pickard, MD; Shi, H; Trepicchio, W	1
Bornmann, W; Ford, RJ; Li, C; Pham, LV; Priebe, W; Tamayo, AT	1
Atadja, P; Balusu, R; Bhalla, KN; Buckley, KM; Coothankandaswamy, V; Fiskus, W; Ha, K; Joshi, A; Nalluri, S; Rao, R; Savoie, A; Sotomayor, E; Tao, J	1
Ajchenbaum-Cymbalista, F; Baran-Marszak, F; Boukhiar, M; Fagard, R; Gressin, R; Harel, S; Laguillier, C; Ledoux, D; Martin, A; Roger, C; Varin-Blank, N	1
Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM	1
Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P	1
Jin, L; Kojima, K; Konopleva, M; Miida, T; Pittaluga, S; Raffeld, M; Tabe, Y; Zhou, Y	1
Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S	1
Chapman, CM; Dunleavy, KM; Liu, P; Maric, I; Mo, CC; Mora-Jensen, H; Pérez-Galán, P; Pittaluga, S; Rader, C; Raghavachari, N; Rizzatti, EG; Shaffer, AL; Staudt, LM; Stennett, LS; Stetler-Stevenson, M; Weniger, MA; Wiestner, A; Wilson, WH; Yuan, C	1
Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C	1
Campo, E; Colomer, D; López-Guerra, M; Mozos, A; Normant, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S	1
Andreeff, M; Asou, H; Inaba, T; Jin, L; Kimura, S; Konopleva, M; Kuroda, J; Miida, T; Tabe, Y; Zhou, Y	1
Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM	1
Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F	1
Assouline, S; Buckstein, R; Chua, NS; Crump, M; Eisenhauer, E; Fernandez, LA; Gascoyne, RD; Klasa, RJ; Kouroukis, CT; Powers, J; Turner, R; Walsh, W	1
Rule, S	1
Anand, M; Armanious, H; Belch, A; Gelebart, P; Lai, R	1
Chott, A; Drach, J; Hoffmann, M; Kaufmann, H; Lamm, W; Raderer, M; Zielinski, C	1
Dunleavy, K; Liu, D; Munson, PJ; Pérez-Galán, P; Raghavachari, N; Rizzatti, EG; Tweito, MM; Wang, Q; Weniger, MA; White, T; Wiestner, A; Wilson, WH; Ye, Y	1
Beaven, AW; Feldman, T; Ferraro, M; Ford, P; Goy, A; Ivanova, A; Moore, DT; Shea, TC; Smith, J	1
Blank, J; Callander, NS; Chang, JE; Choi, S; Eickhoff, JC; Gilbert, LA; Huie, MS; Kahl, BS; Kim, K; Longo, WL; McFarland, TA; Peterson, C; Rogers, ES; Volk, M; Werndli, JE; Yang, DT	1
Jia, L; Joel, SP; Juliger, S; Kassam, S	1
Dong, W; Qian, J; Sun, L; Wang, M; Yang, J; Yi, Q; Zhang, L	1
Alexis Vigier, M; Arakelyan, N; Assouline, D; Bouabdallah, K; Caulet-Maugendre, S; Courby, S; Dartigeas, C; El Yamani, A; Fornecker, L; Gressin, R; Harousseau, JL; Houot, R; Le Gouill, S; Maisonneuve, H; Moles, MP; Mounier, C; Ojeda Uribe, M; Rodon, P; Sutton, L; Tournilhac, O	1
Chen, Z; Fayad, L; Jung, HJ; Kwak, LW; McCarty, N; Romaguera, J; Wang, M	2
Churchill, E; Ma, Y; Mahaffey, CM; Martin, SM; McKnight, H; O'Donnell, RT; Tuscano, JM	1
Dreyling, M; Hiddemann, W; Hutter, G; Pastore, A; Rieken, M; Weigert, O; Weinkauf, M; Zimmermann, Y	1
Brandt, S; Chinratanalab, W; Englehardt, B; Goodman, S; Greer, JP; Jagasia, MH; Kassim, A; Morgan, DS; Oluwole, O; Reddy, N; Savani, BN	1
Jang, WS; Kang, HJ; Kim, A; Lee, JE; Lee, SJ; Lee, SS; Park, S	1
Grant, S; Holkova, B	1
Aggarwal, BB; Ahn, KS; Cheung, LH; Cho, MJ; Ford, RJ; Hittelman, WN; Lyu, MA; Marks, JW; Pham, LV; Rosenblum, MG; Sung, B; Tamayo, AT	1
Chen, Z; Fayad, L; Kwak, LW; McCarty, N; Romaguera, J; Wang, M	1
Chen, Z; Jung, HJ; McCarty, N	1
Joshi, KS; Manohar, SM; Shirsath, NP	1
Camara-Clayette, V; Hermine, O; Ribrag, V	1
Cao, B; Li, J; Mao, X	1
Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H	1
Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M	1
Schenkein, D	1
Ford, RJ; Lo, P; Pham, LV; Tamayo, AT; Yoshimura, LC	1
O'Connor, OA	2
Fisher, RI	1
Adams, J; Choi, E; Dumetrescu, O; Esseltine, D; Hamlin, P; MacGregor-Cortelli, B; Moskowitz, C; Muzzy, J; O'Connor, OA; Portlock, C; Schenkein, D; Straus, D; Stubblefield, M; Trehu, E; Wright, J; Zelenetz, AD	1
Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG	1
Drach, J; Kaufmann, H; Seidl, S	1
Alexandre, J	1
Campo, E; Colomer, D; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N	1
Bogner, C; Decker, T; Peschel, C	1
Moskowitz, CH	1
Coleman, M; Furman, RR; Leonard, JP	1
Bohlius, J; Engert, A; Hülsewede, H; Kober, T	1
Allegue, F; López-Miragaya, MI; Pérez Castro, S; Romo, M	1
Belch, A; Crump, M; Eisenhauer, EA; Gascoyne, RD; Klasa, R; Kouroukis, CT; Powers, J; Sehn, L; Wright, J	1
Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; O'Connor, OA; Robertson, MJ; Shi, H; Stadtmauer, EA	1
Paydas, S	1
Campo, E; Colomer, D; Pérez-Galán, P; Roué, G; Villamor, N	1
Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O	1
Ballestrero, A; Brossart, P; Grunebach, F; Nencioni, A; Patrone, F	1
Amen, K	1
Dagher, R; Farrell, A; Justice, R; Kane, RC; Ko, CW; Pazdur, R; Sridhara, R	1
Han, XH; Kwak, LW; Qian, JF; Romaguera, J; Shi, YK; Wang, M; Yang, J; Yi, Q; Zhang, L	1
Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kloetzel, PM; Kuckelkorn, U; Rademacher, J; Rosche, M; Rötzer, S; Sezer, O; Sterz, J; von Metzler, I	1
Barr, P; Fisher, R; Friedberg, J	1
Brodmann, S; Cathomas, R; Girardi, V; Gyr Klaas, E; von Moos, R	1
Chrysanthopoulou, H; Dimopoulos, MA; Kastritis, E; Matsouka, C; Michopoulos, S; Petraki, K	1
Roberts, AW; Wei, AH	1
Daibata, M; Gibellini, F; Lai, R; Lee, E; Mora-Jensen, H; Rizzatti, EG; Weniger, MA; Wiestner, A	1
Goy, A; Suh, KS	1
Kahl, BS; Markovina, S; Miyamoto, S; Yang, DT; Young, KH	1

Reviews

32 review(s) available for pyrazines and Lymphoma, Mantle-Cell

Article	Year
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Clinical therapeutics, 2019, Volume: 41, Issue:11 Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome	2019
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:1 Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines	2020
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2020
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematology/oncology clinics of North America, 2020, Volume: 34, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2020
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. British journal of haematology, 2021, Volume: 193, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration	2021
Acalabrutinib: First Global Approval. Drugs, 2018, Volume: 78, Issue:1 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration	2018
Use of acalabrutinib in patients with mantle cell lymphoma. Expert review of hematology, 2018, Volume: 11, Issue:6 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2018
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. Drugs, 2018, Volume: 78, Issue:16 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug Therapy, Combination; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2018
Acalabrutinib for adults with mantle cell lymphoma. Expert review of clinical pharmacology, 2019, Volume: 12, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Survival Rate	2019
Acalabrutinib for mantle cell lymphoma. Blood, 2019, 06-13, Volume: 133, Issue:24 Topics: Antineoplastic Agents; Benzamides; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines	2019
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions. Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy	2019
Ibrutinib in B-cell Lymphomas. Current treatment options in oncology, 2014, Volume: 15, Issue:2 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome	2014
Mantle cell lymphoma: evolving management strategies. Blood, 2015, Jan-01, Volume: 125, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Humans; Lymphoma, Mantle-Cell; Medical Oncology; Mutation; Positron-Emission Tomography; Prognosis; Pyrazines; Rituximab; Treatment Outcome	2015
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jul-01, Volume: 65, Issue:13 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrazines	2008
Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents. Current hematologic malignancy reports, 2009, Volume: 4, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Sirolimus; Survival Analysis; Treatment Outcome	2009
Proteasome inhibitors in mantle cell lymphoma. Best practice & research. Clinical haematology, 2012, Volume: 25, Issue:2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Signal Transduction; Survival Analysis	2012
Emerging agents for the treatment of mantle cell lymphoma. Expert review of anticancer therapy, 2012, Volume: 12, Issue:9 Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting	2012
Dissecting bortezomib: development, application, adverse effects and future direction. Current pharmaceutical design, 2013, Volume: 19, Issue:18 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2013
Proteasome inhibitors in the treatment of B-cell malignancies. Clinical lymphoma, 2002, Volume: 3, Issue:1 Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome	2002
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Current treatment options in oncology, 2004, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Risk Assessment; Survival Rate	2004
Proteasome inhibition in the treatment of cancer. Cell cycle (Georgetown, Tex.), 2005, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cyclins; Drug Evaluation, Preclinical; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2005
Treatment of mantle cell lymphoma: targeting the microenvironment. Expert review of anticancer therapy, 2005, Volume: 5, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rituximab; Thalidomide	2005
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leukemia & lymphoma, 2006, Volume: 47, Issue:2 Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship; Ubiquitin	2006
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:3 Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Multicenter Studies as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2005
Mantle cell lymphomas. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11 Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Predictive Value of Tests; Pyrazines; Survival Rate	2005
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International journal of cancer, 2006, Sep-01, Volume: 119, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome	2006
Fourth biannual report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine	2006
The proteasome and its inhibitors in immune regulation and immune disorders. Critical reviews in immunology, 2006, Volume: 26, Issue:6 Topics: Animals; Antigen Presentation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Therapy; Humans; Immune System; Immune System Diseases; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction	2006
The role of bortezomib in the treatment of lymphoma. Cancer investigation, 2007, Volume: 25, Issue:8 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines	2007
Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature. Onkologie, 2007, Volume: 30, Issue:12 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Hyponatremia; Lymphoma, Mantle-Cell; Pyrazines	2007
Bortezomib: putting mantle cell lymphoma on death row. Leukemia & lymphoma, 2008, Volume: 49, Issue:4 Topics: Apoptosis Regulatory Proteins; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines	2008
Bortezomib in mantle cell lymphoma. Future oncology (London, England), 2008, Volume: 4, Issue:2 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome	2008

Trials

33 trial(s) available for pyrazines and Lymphoma, Mantle-Cell

Article	Year
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia, 2019, Volume: 33, Issue:11 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pyrazines; Time Factors; Treatment Outcome	2019
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. Cancer science, 2021, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Headache; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Purpura; Pyrazines; Survival Analysis; Treatment Outcome	2021
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet (London, England), 2018, 02-17, Volume: 391, Issue:10121 Topics: Aged; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome	2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. British journal of haematology, 2019, Volume: 184, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Pyrazines; Syk Kinase; Waldenstrom Macroglobulinemia	2019
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-10, Volume: 31, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide	2013
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer, 2011, Jun-01, Volume: 117, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Proteasome Inhibitors; Pyrazines; Receptors, IgG; Recurrence; Rituximab; Treatment Outcome	2011
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous	2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood, 2014, Mar-13, Volume: 123, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Rituximab; Survival Rate; Vincristine	2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. British journal of haematology, 2014, Volume: 165, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome	2014
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome	2014
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Pyrazines; Treatment Outcome; Vincristine	2015
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. The New England journal of medicine, 2015, Mar-05, Volume: 372, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine	2015
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome	2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas British journal of haematology, 2009, Volume: 145, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Remission Induction	2009
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leukemia & lymphoma, 2009, Volume: 50, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis	2009
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. British journal of haematology, 2009, Volume: 147, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine	2009
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leukemia & lymphoma, 2010, Volume: 51, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Male; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Retrospective Studies; Survival Rate; Treatment Outcome	2010
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica, 2010, Volume: 95, Issue:11 Topics: Aged; Aged, 80 and over; Autocrine Communication; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Humans; Interleukin-10; Interleukin-6; Janus Kinases; Lymphoma, Mantle-Cell; Male; Middle Aged; Phosphorylation; Protease Inhibitors; Pyrazines; Receptors, Antigen, B-Cell; Signal Transduction; STAT3 Transcription Factor	2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer, 2010, Dec-01, Volume: 116, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine	2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. British journal of haematology, 2010, Volume: 151, Issue:1 Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pyrazines; Rituximab; Vincristine	2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. British journal of haematology, 2010, Volume: 151, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia	2010
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood, 2011, Jan-13, Volume: 117, Issue:2 Topics: ADP-ribosyl Cyclase 1; Aged; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lymphoma, Mantle-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines	2011
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-20, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Treatment Outcome; Vincristine; Young Adult	2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, 2011, Mar-10, Volume: 117, Issue:10 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab	2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukemia & lymphoma, 2011, Volume: 52, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Medical Oncology; Middle Aged; National Health Programs; Pyrazines; Recurrence; Societies, Medical	2011
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica, 2011, Volume: 96, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome	2011
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia & lymphoma, 2012, Volume: 53, Issue:2 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Radioimmunotherapy; Salvage Therapy; Survival Rate	2012
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. British journal of haematology, 2011, Volume: 155, Issue:2 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Nervous System Diseases; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Remission Induction; Rituximab; Treatment Outcome; Vincristine	2011
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chlorambucil; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Pyrazines; Rituximab; Treatment Outcome	2012
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Protease Inhibitors; Pyrazines	2005
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Survival Rate; Treatment Outcome	2007
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome	2006
Bortezomib for the treatment of mantle cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 1 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Approval; Female; Humans; Lymphoma, Mantle-Cell; Male; Prospective Studies; Pyrazines; United States; United States Food and Drug Administration	2007

Other Studies

75 other study(ies) available for pyrazines and Lymphoma, Mantle-Cell

Article	Year
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib. Biomolecules, 2022, 05-28, Volume: 12, Issue:6 Topics: Adult; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Metformin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2022
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. Clinical journal of oncology nursing, 2020, 08-01, Volume: 24, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines	2020
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American journal of hematology, 2021, 05-01, Volume: 96, Issue:5 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Substitution; Exome Sequencing; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Sample Size; Treatment Outcome; Withholding Treatment	2021
Acalabrutinib in mantle cell lymphoma. Lancet (London, England), 2018, 02-17, Volume: 391, Issue:10121 Topics: Benzamides; Humans; Lymphoma, Mantle-Cell; Pyrazines	2018
In brief: Acalabrutinib (Calquence) for mantle cell lymphoma. The Medical letter on drugs and therapeutics, 2018, Nov-05, Volume: 60, Issue:1559 Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents, Immunological; Benzamides; Drug Costs; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Treatment Outcome	2018
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. British journal of haematology, 2019, Volume: 187, Issue:5 Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Oncogene, 2014, Apr-24, Volume: 33, Issue:17 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Polycomb Repressive Complex 1; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Side-Population Cells; Up-Regulation	2014
[Right cervical lymph node enlargement]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2013, Volume: 42, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Diagnosis, Differential; Follow-Up Studies; Histiocytic Necrotizing Lymphadenitis; Humans; Infectious Mononucleosis; Ki-67 Antigen; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neck; Pyrazines; SOXC Transcription Factors	2013
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PloS one, 2013, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Pyrazines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2013
Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:6 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Interferons; Lymph Nodes; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Rituximab; Transplantation, Homologous	2013
BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma. PloS one, 2013, Volume: 8, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Morphogenetic Protein 7; Boronic Acids; Bortezomib; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Pyrazines; Recurrence; RNA Interference; Treatment Outcome	2013
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PloS one, 2013, Volume: 8, Issue:9 Topics: Adenosine Triphosphate; Analysis of Variance; Apoptosis; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Casein Kinase II; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Molecular Sequence Data; Multiple Myeloma; Naphthyridines; NF-kappa B; Phenazines; Pyrazines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor	2013
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia, 2014, Volume: 28, Issue:10 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Thalidomide	2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine	2014
Bortezomib treatment for patients with mantle-cell lymphoma. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Pyrazines	2015
CCMCL1: a new model of aggressive mantle cell lymphoma. Blood, 2015, Apr-23, Volume: 125, Issue:17 Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Tumor Cells, Cultured	2015
Bortezomib-based therapy for mantle-cell lymphoma. The New England journal of medicine, 2015, 06-04, Volume: 372, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines	2015
Bortezomib-based therapy for mantle-cell lymphoma. The New England journal of medicine, 2015, 06-04, Volume: 372, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines	2015
Bortezomib-based therapy for mantle-cell lymphoma. The New England journal of medicine, 2015, 06-04, Volume: 372, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines	2015
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2015
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Anti-cancer drugs, 2015, Volume: 26, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin B; Cyclin D1; Cyclin D3; Drug Synergism; Fenretinide; G2 Phase Cell Cycle Checkpoints; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; NF-KappaB Inhibitor alpha; Pyrazines	2015
[Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Formazans; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Neoplasm Proteins; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Purines; Pyrazines; Quinazolinones; Signal Transduction; Software; Tetrazolium Salts	2015
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, Oct-01, Volume: 112, Issue:7 Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays	2008
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, Volume: 22, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mitochondria; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured	2008
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3 Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Imidazoles; Lymphoma, Mantle-Cell; Membrane Proteins; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; Pyrazines; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2009
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis, 2009, Volume: 30, Issue:6 Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Protein Interaction Mapping; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2009
[Bortezomib-induced eruption: Sweet syndrome? Two case reports]. Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:5 Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Colchicine; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Skin Ulcer; Sweet Syndrome; Treatment Outcome	2009
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. British journal of haematology, 2009, Volume: 146, Issue:6 Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Cyproheptadine; Disease Models, Animal; Histamine H1 Antagonists; Histone Deacetylase Inhibitors; Lymphoma, Mantle-Cell; Mice; Protease Inhibitors; Pyrazines	2009
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Humans; Hyperthermia, Induced; Lymphoma, Mantle-Cell; Pyrazines	2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4 Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2004
Captivating bortezomib: an active but still mysterious drug. Leukemia research, 2010, Volume: 34, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Treatment Outcome	2010
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. British journal of haematology, 2010, Volume: 148, Issue:5 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine	2010
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-15, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; Mice; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays	2010
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide. Leukemia research, 2010, Volume: 34, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous	2010
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma. Talanta, 2010, Feb-15, Volume: 80, Issue:4 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence	2010
A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leukemia research, 2010, Volume: 34, Issue:7 Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Division; Cell Line, Tumor; Chymotrypsin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Organometallic Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrones	2010
PRDM1 is required for mantle cell lymphoma response to bortezomib. Molecular cancer research : MCR, 2010, Volume: 8, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Nuclear Proteins; Positive Regulatory Domain I-Binding Factor 1; Proliferating Cell Nuclear Antigen; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Repressor Proteins	2010
Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood, 2010, Nov-18, Volume: 116, Issue:20 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Clone Cells; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lymphocyte Activation; Lymphoma, Mantle-Cell; Mice; Oligodeoxyribonucleotides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retinal Dehydrogenase; Toll-Like Receptor 9; Unfolded Protein Response	2010
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Molecular cancer therapeutics, 2010, Volume: 9, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cyanoacrylates; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; NF-kappa B; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrazines; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Survival Analysis; Xenograft Model Antitumor Assays	2010
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19 Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Fluorescent Antibody Technique; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lymphoma, Mantle-Cell; Mice; Microscopy, Confocal; Panobinostat; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological; Survival Rate; Transcription Factor CHOP; Xenograft Model Antitumor Assays	2010
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer letters, 2010, Dec-28, Volume: 299, Issue:2 Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lymphoma, Mantle-Cell; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53	2010
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. Anticancer research, 2010, Volume: 30, Issue:10 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines	2010
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood, 2011, Jan-27, Volume: 117, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Mice, Transgenic; Middle Aged; Molecular Chaperones; Pyrazines; Receptors, Estrogen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. British journal of cancer, 2011, Jan-04, Volume: 104, Issue:1 Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Coumarins; Cyclin D1; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoprecipitation; Lymphoma, Mantle-Cell; Mutation; Oncogene Protein v-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2011
Velcade combinations in mantle cell lymphoma: are we learning anything? Leukemia & lymphoma, 2011, Volume: 52, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines	2011
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway. Blood, 2011, Jun-09, Volume: 117, Issue:23 Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cysteine Proteinase Inhibitors; Enzyme Activation; Female; Humans; Leupeptins; Lymphoma, Mantle-Cell; Male; Membrane Proteins; Palatine Tonsil; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tonsillar Neoplasms; Transcription Factor RelA; Tumor Necrosis Factor-alpha	2011
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-01, Volume: 17, Issue:15 Topics: Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Gene Expression Profiling; Humans; Lymphoma, Mantle-Cell; NF-E2-Related Factor 2; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Transcription, Genetic; Tumor Cells, Cultured	2011
Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins. British journal of haematology, 2012, Volume: 156, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Interactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Organoselenium Compounds; Proto-Oncogene Proteins c-bcl-2; Pyrazines	2012
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leukemia research, 2012, Volume: 36, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; In Vitro Techniques; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pyrazines; Spiro Compounds; Survival Rate	2012
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Experimental hematology, 2012, Volume: 40, Issue:2 Topics: Antigens, CD19; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Leukocyte Common Antigens; Lymphoma, Mantle-Cell; Neoplastic Stem Cells; NF-kappa B; Pyrazines	2012
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. Journal of hematology & oncology, 2011, Dec-01, Volume: 4 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 2; Xenograft Model Antitumor Assays	2011
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Annals of hematology, 2012, Volume: 91, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Lymphoma, Mantle-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2012
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Experimental hematology, 2012, Volume: 40, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine	2012
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood, 2012, Mar-15, Volume: 119, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; GTP-Binding Proteins; Humans; Immunoenzyme Techniques; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Monoterpenes; NF-kappa B; Perilla; Protein Glutamine gamma Glutamyltransferase 2; Pyrazines; Transglutaminases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2012
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leukemia research, 2012, Volume: 36, Issue:7 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Imidazoles; Lymphoma, Mantle-Cell; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinolines; TOR Serine-Threonine Kinases	2012
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochemical pharmacology, 2012, Aug-15, Volume: 84, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Recombinant Fusion Proteins; Ribosome Inactivating Proteins, Type 1; Signal Transduction; Toxins, Biological; Transplantation, Heterologous	2012
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. British journal of haematology, 2012, Volume: 159, Issue:2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vasodilator Agents; Verapamil	2012
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. American journal of hematology, 2012, Volume: 87, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines	2012
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Molecular cancer, 2012, Oct-18, Volume: 11 Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazines; RNA, Small Interfering; Survival Analysis; Xenograft Model Antitumor Assays	2012
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British journal of haematology, 2013, Volume: 161, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured	2013
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leukemia & lymphoma, 2013, Volume: 54, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors	2013
Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. Journal of immunology (Baltimore, Md. : 1950), 2003, Jul-01, Volume: 171, Issue:1 Topics: Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-X Protein; Biopsy; Boronic Acids; Bortezomib; Cell Cycle; Growth Inhibitors; Humans; Hydrolysis; I-kappa B Proteins; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Minor Histocompatibility Antigens; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Organic Chemicals; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Cells, Cultured	2003
Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines	2005
[Proteasome inhibitors]. La Revue de medecine interne, 2005, Volume: 26, Issue:10 Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured	2005
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, Jan-01, Volume: 107, Issue:1 Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Free Radical Scavengers; Humans; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation	2006
[Recurrent varicella in a woman with mantle cell lymphoma]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chickenpox; Combined Modality Therapy; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Middle Aged; Postoperative Complications; Pyrazines; Recurrence; Transplantation, Autologous	2006
Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma? Leukemia & lymphoma, 2006, Volume: 47, Issue:11 Topics: Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, Mantle-Cell; Microtubule-Associated Proteins; Neoplasm Proteins; NF-kappa B; Pyrazines; Survivin	2006
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood, 2007, May-15, Volume: 109, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, Mantle-Cell; Molecular Mimicry; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Peptide Fragments; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured	2007
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 2007, Volume: 21, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes	2007
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now? ONS connect, 2007, Volume: 22, Issue:8 Suppl Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide	2007
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia, 2008, Volume: 22, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Cyclophosphamide; Drug Synergism; Immunophenotyping; In Vitro Techniques; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Poly(ADP-ribose) Polymerases; Pyrazines; Rituximab; Survival Rate; Transplantation, Heterologous	2008
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. European journal of haematology, 2008, Volume: 80, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Treatment Outcome; Vorinostat	2008
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; Prednisone; Prognosis; Pyrazines; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine	2008
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leukemia & lymphoma, 2008, Volume: 49, Issue:4 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; NF-kappa B; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Up-Regulation	2008
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Molecular cancer, 2008, May-19, Volume: 7 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2008